The pharmaceutical company PrJSC Darnitsa (Kyiv) has registered a drug in Bosnia and Herzegovina for the treatment and prevention of neuromuscular transmission disorders, including myasthenia gravis, stimulation of the intestines and bladder after surgery, and restoration of muscle activity after anesthesia.
According to a press release from the company, the drug was registered at the end of December.
The registration certificate is valid for five years.
As previously reported, Darnitsa also registered an antifungal drug in Bosnia and Herzegovina.
Currently, Darnitsa’s drugs are available in more than 20 countries around the world.
Darnitsa has been operating on the market for over 90 years, is one of the ten largest pharmaceutical manufacturers in Ukraine, and produces 180 brands of drugs in 15 different forms. The strategic areas of portfolio development are cardiology, neurology, and pain management.
The net loss of PJSC “Pharmaceutical Firm ”Darnitsa“” (Kyiv) in January-June 2025 amounted to UAH 479.473 million, while in the same period of 2024, the company received a net profit of UAH 6.528 million. According to the Unified State Register of Legal Entities and Individual Entrepreneurs, the ultimate beneficiary of the company is Gleb Zagoriy.
